Navigation Links
ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
Date:1/8/2009

at this first dose tested in the Phase Ib study," commented James Freddo, M.D., Anadys' Senior Vice President, Drug Development and Chief Medical Officer. "We believe this early data continues to position ANA598 as a leading non-nucleoside polymerase inhibitor in development for the treatment of HCV and we look forward to investigating ANA598 in longer-term studies in combination with current standard of care."

"The clinical and preclinical profile of ANA598 observed to date is very impressive," said Steve Worland, Ph.D., President and CEO of Anadys. "The magnitude of viral load drop reported today for ANA598 is greater than has been reported for any other non-nucleoside HCV inhibitor in a monotherapy study. Furthermore, the rate of initial viral load decline, believed to be associated with direct inhibition of viral replication, is greater than has been reported previously for all classes of HCV polymerase inhibitors, including nucleosides. This demonstrated antiviral potency holds significant promise for the future use of ANA598 in combination with other anti-HCV agents."

About ANA598

Anadys retains worldwide rights to ANA598, which was fully discovered at the Company. Preclinical evaluation of ANA598 was completed in the first quarter of 2008, leading to submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA), subsequent allowance of the IND by the FDA and initiation of clinical investigation in the second quarter of 2008. In December 2008, Anadys announced that the FDA granted fast track designation to ANA598 for the treatment of chronic HCV.

In October 2008, Anadys initiated patient dosing in the Phase Ib study of ANA598 in HCV patients. In the double-blind, randomized placebo-controlled Phase Ib study, treatment-naive genotype 1a and 1b patients are to receive oral capsules of ANA598 over three days at doses of 200 mg bid (twice
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
8. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Organovo Holdings, Inc. ... focused on delivering breakthrough 3D bioprinting technology, announced ... Chief Executive Officer, will present live at VirtualInvestorConferences.com ... you to join us for this Company update," ... on our commercial launch of the exVive3D Liver, ...
(Date:2/27/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today announced that ... on Tuesday, March 10, 2015. Rob Kill , ... Financial Officer, will present at 4:00 p.m. Pacific Time ... conference at the Ritz Carlton in Laguna ...
(Date:2/27/2015)... NEWTON, Mass. and JERUSALEM ... privately-held biopharma company developing octreotide capsules, its lead product ... of a $70 million Series E financing round. Participants ... and Sofinnova Ventures, and an undisclosed blue chip public ... F2 Capital, 7 Med Health Ventures, Abingworth and ARCH ...
Breaking Medicine Technology:Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
... Inc. (NASDAQ: UPI ), a medical ... proprietary products to treat voiding dysfunctions, today announced ... covering the stimulator used in the Urgent® PC ... an office-based, non-surgical system, used to treat overactive ...
... LCAV ), a leading provider of laser vision correction ... management will present at the Lazard Capital Markets 8th Annual ... Eastern time. The conference is being held at the Pierre ... of the presentation will be available at the Investor Relations ...
Cached Medicine Technology:Uroplasty Announces Issuance of New Apparatus Patent for the Urgent® PC Neuromodulation System Stimulator 2
(Date:2/27/2015)... OnChip Devices , a world leader ... bondable, silicon ESD (Electrostatic Discharge) protection diodes targeted for ... ESD88NP and ESD88PN are designed to ... IC products. These Zeners exhibit no device degradation ... meet the requirements of IEC61000 and safely dissipate ESD ...
(Date:2/27/2015)... Those who self-injure, commonly ... misdiagnosed and therefore aren’t receiving effective treatment ... Jacksonville-based addiction treatment center Lakeview Health has ... Lakeview Professional Lecture Series to counselors, physicians, ... complicated condition. , “Self-injurious behaviors ...
(Date:2/27/2015)... 27, 2015 Clinovo, a leading provider ... Electronic Data Capture (EDC) at the CALBIO2015 ... 2nd and March 3rd at Booth # 141. ... DIY CRF and edit-check builder allowing Clinical Trials Managers ... of days, without any programming experience. Clinovo’s new pricing ...
(Date:2/27/2015)... 27, 2015 Pipette.com announces their limited ... price is only valid until the end of March ... for a vortex mixer that allows for absolute control ... in 1954 and is headquartered in Bohemia, New York. ... as well as other rockers, incubators, and hybridization ovens ...
(Date:2/27/2015)... February 27, 2015 Undocumented farmworkers ... documented to use Medicaid, the federal health insurance ... to a new study from UC Davis Health ... predictor of farmworker use of Medicaid, which provides ... of documentation status, was having children. , ...
Breaking Medicine News(10 mins):Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 2Health News:OnChip Introduces New Series of Space Saving Bare-die Zener Diodes for Transient Voltage Suppression 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2Health News:Clinovo to Demo Its Self-Service, Cloud-Based EDC Solution at CALBIO2015 on March 2nd and 3rd, 2015 2Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 2Health News:UC Davis Study Finds Undocumented Farmworkers Use Medicaid Half as Often as Documented Farmworkers 3
... toxins enter the cells, but before the toxins can kill, ... brain cancer cells are even better than healthy cells at ... cells tend to die before brain cancer cells. Especially in ... the University of Colorado Cancer Center have discovered a way ...
... an HIV-infected partner is the single most important factor influencing ... a multinational study of heterosexual couples in sub-Saharan Africa. The ... calculated the risk of HIV-1 transmission per act of sexual ... about 1 per 900 coital acts. The findings also confirmed ...
... The ideal number of embryos to implant during in-vitro fertilization ... be more than three, according to a new study that ... about 124,000 IVF cycles that resulted in 33,500 live births. ... ages who had two embryos implanted than among those who ...
... News) -- A genetic mutation that causes a rare ... has been identified by scientists. Symptoms of the ... hives (cold urticaria), according to the report published online ... England Journal of Medicine . The U.S. National ...
... News) -- A small study that offers new insight into ... effective treatments for people with drinking problems. Researchers used ... alcohol in the brains of 13 heavy drinkers and a ... In all of the participants, drinking alcohol triggered the ...
... MADISON Placing a stent in a key artery in the ... standard surgical treatment of carotid artery disease, according to a ... Vascular Surgery . A team of researchers led ... at University of Wisconsin School of Medicine and Public Health, ...
Cached Medicine News:Health News:Selectively stopping glutathione sensitizes brain tumors to chemotherapy 2Health News:Viral load a major factor affecting risk of sexually transmitting HIV 2Health News:Viral load a major factor affecting risk of sexually transmitting HIV 3Health News:Three Embryos Are Too Many for IVF: Study 2Health News:Gene Research Sheds Light on Rare Immune Disease 2Health News:Alcohol Targets Brain 'Reward Centers' in Heavy Drinkers 2Health News:Stenting for stroke prevention becoming safer in high-risk patients 2
... has been selling replacement bulbs ... and we are extremely proud ... Check out our catalog of ... discount light bulbs specials. ...
... Bulb Direct has been ... Internet since 1996, and we ... 100% satisfaction guarantee. Check out ... and see our discount light ...
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
A dual chamber sensing/pacing, rate responsive, 31 J ICD, with ELA's patented PARAD/PARAD+ ventricular tachycardia algorithm....
Medicine Products: